326 related articles for article (PubMed ID: 37486536)
21. Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.
da Costa AA; D'Almeida Costa F; Ribeiro AR; Guimarães AP; Chinen LT; Lopes CA; de Lima VC
Int J Clin Oncol; 2015 Apr; 20(2):282-9. PubMed ID: 24858479
[TBL] [Abstract][Full Text] [Related]
22. Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis.
de Ruiter EJ; Bisheshar SK; de Roest RH; Wesseling FWR; Hoebers FJP; van den Hout MFCM; Leemans CR; Brakenhoff RH; de Bree R; Terhaard CHJ; Willems SM
Virchows Arch; 2022 Aug; 481(2):223-231. PubMed ID: 35451620
[TBL] [Abstract][Full Text] [Related]
23. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
25. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
26. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
[TBL] [Abstract][Full Text] [Related]
28. Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.
Stein AP; Swick AD; Smith MA; Blitzer GC; Yang RZ; Saha S; Harari PM; Lambert PF; Liu CZ; Kimple RJ
Cancer Med; 2015 May; 4(5):699-712. PubMed ID: 25619980
[TBL] [Abstract][Full Text] [Related]
29. PTEN Expression, Not Mutation Status in
Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
Ou D; Garberis I; Adam J; Blanchard P; Nguyen F; Levy A; Casiraghi O; Gorphe P; Breuskin I; Janot F; Temam S; Scoazec JY; Deutsch E; Tao Y
Radiother Oncol; 2018 Jan; 126(1):116-124. PubMed ID: 29079308
[TBL] [Abstract][Full Text] [Related]
31. miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.
Vahabi M; Pulito C; Sacconi A; Donzelli S; D'Andrea M; Manciocco V; Pellini R; Paci P; Sanguineti G; Strigari L; Spriano G; Muti P; Pandolfi PP; Strano S; Safarian S; Ganci F; Blandino G
J Exp Clin Cancer Res; 2019 Mar; 38(1):141. PubMed ID: 30925916
[TBL] [Abstract][Full Text] [Related]
32. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
34. Combined P16 and human papillomavirus testing predicts head and neck cancer survival.
Salazar CR; Anayannis N; Smith RV; Wang Y; Haigentz M; Garg M; Schiff BA; Kawachi N; Elman J; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
Int J Cancer; 2014 Nov; 135(10):2404-12. PubMed ID: 24706381
[TBL] [Abstract][Full Text] [Related]
35. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
[TBL] [Abstract][Full Text] [Related]
36. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
[TBL] [Abstract][Full Text] [Related]
37. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.
Rampias T; Pectasides E; Prasad M; Sasaki C; Gouveris P; Dimou A; Kountourakis P; Perisanidis C; Burtness B; Zaramboukas T; Rimm D; Fountzilas G; Psyrri A
Ann Oncol; 2013 Aug; 24(8):2124-31. PubMed ID: 23406730
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab.
Patel U; Kannan S; Rane SU; Mittal N; Gera P; Patil A; Manna S; Shejwal V; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
Br J Cancer; 2022 Jun; 126(10):1439-1449. PubMed ID: 35140342
[TBL] [Abstract][Full Text] [Related]
39. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma.
Deng Z; Hasegawa M; Aoki K; Matayoshi S; Kiyuna A; Yamashita Y; Uehara T; Agena S; Maeda H; Xie M; Suzuki M
Int J Oncol; 2014 Jul; 45(1):67-76. PubMed ID: 24820457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
